IRB #

STUDY00019207

Title

A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) and Lenvatinib (E7080/MK-7902) Versus Pembrolizumab Alone as First-line Intervention in Participants with Advanced Melanoma (LEAP-003)

Principal Investigator

Matthew Taylor

Study Purpose

The purpose of this study is to:
- See how well the combination of study drugs (lenvatinib and pembrolizumab) work together
- Test the safety and how well your body handles the combination of the study drugs
- Find out how lenvatinib is absorbed and broken down in your body when given with pembrolizumab
- Test the combination of the study drugs and see if they help patients live longer

Medical Condition(s)

Unresectable Stage III or Stage IV melanoma.

Eligibility Criteria

Male and Female participants of 18 years of age and older.
Unresectable Stage III or Stage IV melanoma.

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Up to 2 years of treatment and you will be contacted by the investigator or study team approximately every 12 weeks or more often to check on your health indefinitely.

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080

Sponsor

Merck Sharp & Dohme Corp.

Recruitment End

12/31/2019

Compensation Provided

No


Go Back